DRRX - DURECT Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.95
-0.03 (-1.52%)
At close: 4:00PM EDT

1.95 -0.00 (-0.02%)
After hours: 4:37PM EDT

Stock chart is not supported by your current browser
Previous Close1.98
Open1.98
Bid1.95 x 36200
Ask2.01 x 38800
Day's Range1.85 - 2.02
52 Week Range0.75 - 2.55
Volume731,781
Avg. Volume789,751
Market Cap315.333M
Beta2.22
PE Ratio (TTM)N/A
EPS (TTM)-0.03
Earnings DateMay 8, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.83
Trade prices are not sourced from all markets
  • GlobeNewswire15 days ago

    New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star Resources, and Loxo Oncology — Consolidated Revenues, Company Growth, and Expectations for 2018

    NEW YORK, June 07, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Durect ...

  • ACCESSWIRE15 days ago

    Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks

    Stock Research Monitor: ZGNX, DEPO, and DRRX LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want a free Stock Review on ENDP sign up now at www.wallstequities.com/registration . Ahead of today's trading ...

  • ACCESSWIRE18 days ago

    DURECT Corporation Approaching PDUFA Dates and Analysts Review

    NEW YORK, NY / ACCESSWIRE / June 4, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on DURECT Corporation (DRRX) a biopharmaceutical company actively developing new therapeutics based on its Epigenetic Regulator Program and proprietary drug delivery platforms. As of May 5, 2017, DURECT held over 55 issued U.S. patents and over 355 issued foreign patents (which include granted European patent rights that have been validated in various EU member states). In addition, they have over 35 pending U.S. patent applications and over 100 foreign applications pending in Europe, Australia, Japan, Canada, and other countries.

  • PR Newswirelast month

    DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine)

    DURECT received an upfront payment from Sandoz of $20 million at the time the agreement between the two companies became effective in June 2017 and was initially eligible for up to an additional $43 million in payments based on successful development and regulatory milestones (of which $30 million is feasible following the results of the PERSIST Phase 3 clinical trial), and up to an additional $230 million in sales-based milestones.  Sandoz received exclusive commercialization rights for POSIMIR in the U.S. upon regulatory approval with sole funding responsibility for commercialization activities.  Sandoz has agreed to pay DURECT a tiered double-digit royalty on product sales for a defined period. Pursuant to the amended agreement, DURECT is now eligible for up to $30 million in milestone payments based on NDA approval, and remains eligible for up to an additional $230 million in sales-based milestones.  Each party, pursuant to the Amendment, is also permitted to develop or commercialize competing products.  The Amendment also includes modifications to DURECT's development obligations and to both parties' termination provisions, including a right for DURECT to terminate for convenience prior to NDA approval.

  • Want To Invest In DURECT Corporation (NASDAQ:DRRX)? Here’s How It Performed Lately
    Simply Wall St.last month

    Want To Invest In DURECT Corporation (NASDAQ:DRRX)? Here’s How It Performed Lately

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine DURECT Corporation’s (NASDAQ:DRRX) track record on a high level, to giveRead More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of DRRX earnings conference call or presentation 2-May-18 8:30pm GMT

    Q1 2018 DURECT Corp Earnings Call

  • Associated Press2 months ago

    Durect: 1Q Earnings Snapshot

    The Cupertino, California-based company said it had a loss of 5 cents per share. The specialty pharmaceutical company posted revenue of $3.5 million in the period. In the final minutes of trading on Wednesday, ...

  • PR Newswire2 months ago

    DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update

    Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , May 2, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended ...

  • PR Newswire2 months ago

    DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis

    CUPERTINO, Calif., April 25, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with alcoholic hepatitis (AH).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in diseases such as nonalcoholic steatohepatitis (NASH) and other disorders of the liver such as PSC, in acute organ injuries such as acute liver and kidney injury, and in inflammatory skin disorders such as psoriasis and atopic dermatitis. "There is a clear unmet medical need to find effective medical therapy in acute alcoholic hepatitis, so we look forward to seeing how these patients respond when treated with this intravenously administered endogenous small molecule," stated Dr. Lance Stein, MD, Piedmont Atlanta Hospital.  This is one of 5 sites planned for this study and the first site to enroll a patient.

  • PR Newswire2 months ago

    DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call

    CUPERTINO, Calif., April 24, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's(DRRX) first quarter 2018 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Wednesday, May 2, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast of the presentation will be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

  • PR Newswire3 months ago

    DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis

    CUPERTINO, Calif., March 29, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of alcoholic hepatitis (AH) on Thursday, April 5 at 11:00 a.m. Eastern Time. The call will feature a presentation by KOL Paul Kwo, MD, who will present an overview of alcoholic hepatitis, including an overview of the disease and its progression, current treatment options and new treatments in development for alcoholic hepatitis.  Dr. Kwo will be available to answer questions at the conclusion of the call. DURECT's management team will also provide an overview of the Company's ongoing clinical development program for DUR-928, including a summary of preclinical and clinical data disclosed to-date and a review of the Company's Phase 2 study in patients with alcoholic hepatitis.  DUR-928 is the lead product candidate in DURECT's Epigenetic Regulator Program.  It is an endogenous, first-in-class small molecule that has been shown in nonclinical studies to modulate the activity of nuclear receptors playing an important regulatory role in lipid homeostasis, inflammation, and cell survival.

  • GlobeNewswire3 months ago

    Investor Expectations to Drive Momentum within Aon plc, Endeavour Silver, BlackBerry, DURECT, Castle Brands, and Nabors Industries — Discovering Underlying Factors of Influence

    NEW YORK, March 26, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • PR Newswire3 months ago

    DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER

    CUPERTINO, Calif. , March 20, 2018 /PRNewswire/ --   DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that the U.S. Food and Drug ...

  • Is DURECT Corporation (NASDAQ:DRRX) Undervalued?
    Simply Wall St.3 months ago

    Is DURECT Corporation (NASDAQ:DRRX) Undervalued?

    DURECT Corporation (NASDAQ:DRRX), a pharmaceuticals company based in United States, led the NasdaqGM gainers with a relatively large price hike in the past couple of weeks. As a small capRead More...

  • Benzinga4 months ago

    Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors

    DURECT Corporation (NASDAQ: DRRX ) has had a rough few months since the failure of a Phase 3 trial for its formerly leading drug candidate. Days after reporting top- and bottom-line quarterly beats, the ...

  • Associated Press4 months ago

    Durect tops 4Q revenue forecasts

    On a per-share basis, the Cupertino, California-based company said it had net income of 5 cents. The specialty pharmaceutical company posted revenue of $19.5 million in the period, which topped Street ...

  • PR Newswire4 months ago

    DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs

    Live Webcast of Earnings Call Today at 4:30 p.m. Eastern Time CUPERTINO, Calif. , March 1, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ...

  • PR Newswire4 months ago

    DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC)

    CUPERTINO, Calif., Feb. 26, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it has commenced patient dosing in a Phase 2a clinical trial of DUR-928 in patients with primary sclerosing cholangitis (PSC).  DUR-928, the lead investigational product in our Epigenetic Regulator Program, is an endogenous, first-in-class small molecule, which may have broad applicability in several hepatic and renal diseases such as nonalcoholic steatohepatitis (NASH) and other disorders of the liver such as PSC, in acute organ injuries such as acute liver and kidney injury, and in inflammatory skin disorders such as psoriasis and atopic dermatitis. "There is a clear unmet medical need to find effective medical therapy in PSC and prevent progression to end stage liver disease, so we look forward to seeing how these patients respond when treated with this orally administered endogenous small molecule," stated Dr. Kidist K. Yimam, Medical Director, Autoimmune Liver Disease Program at California Pacific Medical Center, Department of Hepatology and Liver Transplantation, San Francisco, CA.  This is one of 15 sites planned for this study and the first site to enroll a patient.

  • PR Newswire4 months ago

    DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call

    CUPERTINO, Calif., Feb. 22, 2018 /PRNewswire/ -- In conjunction with DURECT Corporation's (DRRX) fourth quarter 2017 financial results press release, you are invited to listen to a conference call that will be broadcast live over the internet on Thursday, March 1, 2018 at 4:30 pm Eastern Time (1:30 pm Pacific Time). A live audio webcast of the presentation will be available by accessing DURECT's homepage at www.durect.com and clicking "Investor Relations."  If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.

  • PR Newswire4 months ago

    DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC)

    CUPERTINO, Calif., Feb. 20, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced it will host a key opinion leader (KOL) call on the treatment of primary sclerosing cholangitis (PSC) on Monday, February 26 at 12:00 p.m. Eastern Time. The call will feature a presentation by KOL Keith Lindor, MD, who will present an overview of primary sclerosing cholangitis, including an overview of the disease and its progression, current treatment options and the treatment landscape for PSC.  He will be available to answer questions at the conclusion of the call. Dr. Keith Lindor is Senior Advisor to the Provost at Arizona State University (ASU) and a Professor of Medicine at Mayo Clinic.

  • PR Newswire4 months ago

    DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics

    CUPERTINO, Calif. , Feb. 14, 2018 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that its licensee, Pain Therapeutics (Nasdaq: PTIE), reported yesterday that it has resubmitted the New ...

  • PR Newswire6 months ago

    DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot

    CUPERTINO, Calif. , Dec. 13, 2017 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced that Indivior PLC (LON: INDV) has reported that the U.S. Food and Drug Administration (FDA) has accepted ...

  • ACCESSWIRE6 months ago

    DURECT Corporation: New Patent Revenue, Analysts Review, Earnings and Current Pipeline Progress

    NEW YORK, NY / ACCESSWIRE / December 12, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • Capital Cube6 months ago

    ETFs with exposure to DURECT Corp. : December 11, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to DURECT Corp. Here are 5 ETFs with the largest exposure to DRRX-US. Comparing the performance and risk of DURECT Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)